Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04681131 · ClinicalTrials.gov registry record · Phase 2
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by BioAtla.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
- 20
- Study locations
NCT04681131: Completed Phase 2 study of Non-Small Cell Lung Cancer, sponsored by BioAtla.
NCT04681131 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by BioAtla. The registered enrollment target is 85 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04681131, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by BioAtla.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC
Primary Outcome
Proportion of patients who achieve a confirmed CR or PR according to RECIST v1.1
Conditions Studied
Interventions
- BIOLOGICAL PD-1 inhibitor
- BIOLOGICAL CAB-AXL-ADC
Study Locations (20)
California
- City of Hope - Duarte - Duarte
- University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center - Irvine
- California Research Institute - Los Angeles
- USC Norris - Los Angeles
- Cedars-Sinai - Los Angeles
- University of California, San Diego (UCSD) - Moores Cancer Center - San Diego
- American Institute of Research - Whittier
Florida
- Florida Cancer Specialists & Research Institute - Fleming Island
- Florida Cancer Specialists & Research Institute - Fort Myers
- Florida Cancer Specialist - St. Petersburg
- Moffitt Cancer Center - Tampa
- Florida Cancer Specialists - West Palm Beach
Kentucky
- Baptist Health Systems - Lexington
- University of Kentucky - Lexington
- Norton Cancer Institute, Brownsboro Hospital Campus - Louisville
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Georgia
- Augusta University - Georgia Cancer Center - Augusta
Louisiana
- Hematology/Oncology Clinic - Baton Rouge
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- University of Michigan Comprehensive Cancer Center - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2025-07-09 |
| Phase | Phase 2 |
What the finished NCT04681131 record still lists
NCT04681131 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which PD-1 inhibitor is the first listed.
NCT04681131 names 20 study sites across 8 states, led by California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT04681131 about?
NCT04681131 is a clinical study titled "CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC". The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC
What is the current status of trial NCT04681131?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2021-03-17. Estimated completion is 2025-07-09.
What conditions does trial NCT04681131 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT04681131?
The interventions under investigation include: PD-1 inhibitor (BIOLOGICAL), CAB-AXL-ADC (BIOLOGICAL).
Who is sponsoring clinical trial NCT04681131?
This trial is sponsored by BioAtla, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04681131 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04681131's enrollment target sits among peer trials
85 259th of 454 higher than 192 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI